Contemplate Synthetic and Herbal origin provisions for non-enzymatic Glycation (NEGs) inhibition
Abstract
No abstract
References
1. Sarah W, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047-53.
2. Centre for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
3. Horiuchi S. Advanced glycation end products (AGE)- modified proteins and their potential relevance to atherosclerosis. Trend Cardiovasc. Med.1996;6:163-168.
4. Araki N, Ueno N, Chakrabarti B, Morino Y and Horiuchi S. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem.1992;267:10211- 10214.
5. Vorum H, Fisker K, Otagiri M, Pedersen A O and Hansen U. K. Calcium ion binding to clinically relevant chemical modifications of human serum albumin. Clin. Chem.1995;41:1654-1661.
6. Peters T. In All About Albumin: Biochemistry, Genetics, and Medical Applications. Academic Press: San Diego,1996;12; 102-126.
7. Iberg N and Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. J. Biol.Chem.1986;261; 13542-13545.
8. Stewart I. I, Thomson T and Figeys D. 18O labeling: A tool for proteomics. Rapid.J. 2001;34:12-18.
9. Schnolzer M, Jedrzejewski P and Lehmann WD. Proteasecatalyzedincorporation of 18O intopeptide fragments and its application for protein225sequencing by electrospray and matrix-assisted laser desorption/ionization massspectrometry. Electrophoresis. 2005;17:945-953.
10. Wa C, Cerny L and Hage D S. Identification and quantitative studies of protein immobilization sites by stable isotope labeling and mass spectrometry. Anal.Chem.2006;78:7967- 7977.
11. Armbuster D. A Fructosaminase: Structure, analysis and clinical usefulness. Clin. Chem.1987;33:2153-2163.
12. Abordo E A and Thornalley P J. In Pro-inflammatory cytokine synthesis by humanmonocytes induced by proteins minimally-modified by methylglyoxal. TRSC: Cambridge, UK, 1998;12; 357-362.
13. Kouzuma T, Usami T, Yamakoshi M, Takahashi M and Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin. Chim. Acta. 2002;324:61-71.
14. Lapolla A, Fedele D, Seraglia R, Catinella S, Baldo L, Aronica R and Traldi P A. New effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia.1995;38:1076-1081.
15. Mirgorodskaya O A, Kozmin Y P, Titov M I., Korner R, Sonksen C P and Roepstorff P. Quantitation of peptides and proteins by matrix-assisted laser desorption/ionization mass spectrometry using 18O-labeled internal standards. Rapid. Comm. Mass. Spec. 2000;14:1226-1232.226.
16. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T. Iwaki M, Bucahe R and Yamagishi S. Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr. Alzheimer Res.2004;1:39-46.
17. Basta G, Schmidt A M and Decaterina R. Advanced glyca- tion end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovascular Research. 2004;63:582-592.
18. Cerami A, Stevens V J and Monnier V M. Role of nonenzymatic glycosylation in the development of the squealed of diabetes mellitus. Metabolism. 1979;28:431-437.
19. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. Journal of Hypertension, 2003;21:3-12
20. Peyroux J and Sternberg M. Advanced glycation endproducts (AGEs):Pharmacological inhibition in diabetes. Pathol Biol. 2006;54:405-419.
21. Schmidt H, Hofmann H and Henary M. No NO from NO synthase. Proc Nat Aad Sci USA. 1996;93:13712-13717
22. Saxena P, Saxena A K and Monnier V M. High galactose levels in vitro and in vivo impair ascorbate regeneration and increase ascorbate-mediated glycation in cultured rat lens. Exper. Eye Res.1996;63:535-545.
23. Kyselova Z, Stefek M and Bauer V. Pharmacological prevention of diabetic cataract. J.Diab.Compli. 2004;18:129-140.
24. Khalifah R G, Baynes J W and Hudson B G. Amadorins: novel post-Amadori inhibitors of advancedglycation reactions. Biochem. Biophys. Res.Commun.1999;257:251-258.
25. Kousar K. Diabetices & metabolisms (2007),32:123-129.
26. Lubeg G, Widness J A, Hayde M, Menzel D and Pollak A. Hydroxyl radical generation in oxygen-treated infants. Pediatrics. 1997;100:700-704.
27. McLean WG. The role of axonal cytoskeleton in diabetic neuropathy. Neurochem Res. 1997;22:951-956.
28. Bonnefont-Rousselot, D. Antioxidant and anti-AGE therapeutics, J Soc Biol. 2001;195(4):391-398.
29. Jin-Bae K, Byeong W, Sungha P, Ki-Chul H, Bong-Soo C, Yangsoo J, Hyun,C La nd Moon-Hyoung L. Alagebrium Chloride, a Novel Advanced Glycation End-Product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. KCJ. 2010;40:520-526.
30. Nilsso E H. Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy. Drugs Aging. 1999;12(4);277-292.
31. Thornalley P J. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003;31:1343-1348.
32. Rahbar S and Figarola J L. Novel inhibitors of advanced glycation end products. Endocrinol. Metab. Agents. 2002;2;:135– 161.
33. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N and Nadler J L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta. 2000;301(1-2):65-77.
34. Sakai M, Oimomi M and Kasuga M. Experimental studies on the role of fructose in the development of diabetic complications. Kobe J. Med. Sci. 2002;48(5-6):125-136.
35. Rackovsky S and Scheraga H A. The crystal structure of a hydrated gramicidin S–urea complex. Proc. Natl Acad. Sci. USA.1980;77:6965–6967
36. Jyothirmayi G. Effects of Metformin on collagen glycation and diastolic dysfunction. Pharmacol Ther. 1998;3:319-326.
37. Beisswenger J P, Howell S K and Touchette A. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 2002;48 (1):198-202.
38. Stitt A, Gardiner T, Alderson N, Canning P, Frizzel N, Duffy N, Boyle C, Januszewski A, Chachich M, Baynes J W and Thorpe S R. The AGE inhibitor pyridoxamine inhibits development of retinopathy inexperimental diabetes. Diabetes. 2002;51:2826-2832.
39. Alderson N L, Chachich M E, Youssef N N, Beattie R J, Nachtigal M, Thorpe R and Baynes J W. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 2003;63:2123-2133.
40. Metz T O, Alderson N L, Chachich M E, Thorpe S R and Baynes J W. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003;278:42012-42019.
41. Fu M X, Wells K, Blackledge J A, Lyons T J, Thorpe S R and Baynes J W. Glycation, glycoxidation, and cross-linking of collagen by glucose.Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676- 683.
42. Voziyan P A and Hudson B G. “Pyridoxamine as a multifunctionalpharmaceutical: targeting pathogenic glycation and oxidative damage.” Cell Mol Life Sci. 2005;62(15):1671- 81.
43. Baynes J W. The role of AGEs in aging: Causation or correlation. Exp. Gerontol.1991;36:1527-1537.
44. McPherson J D, Shilton B H and Walton D J. Role of fructose in glycation and cross-linking of proteins. Biochemistry. 1998;27(6):.1901-1907.
45. Menzel E J, Reihsner R. Novel inhibitors of advanced glycation end products. Diabetologia. 1991;3412-16.
46. Zhang C, Sun A, et al. “Aspirin for primary prevention of cardiovascular events in patients with diabetes: A metaanalysis. Diabetes Res Clin Pract . 2010;87(2): 211-218.
47. Ahmed N. Advanced glycation endproducts role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005;67:3-21.
48. Duraisamy Y, Gaffney J, Slevin M, Smith CA, Williamson K, Ahmed N. Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia,advancedglycation endproducts and glycated basic fibroblast growth factor in cultured bovineaorticendothelial cells: comparison with aminoguanidine. Molecular and Cellular Biochemistry. 2003;246:143– 153.
49. Forbes J M, Soulis T and Thallas V. Renoprotective effects of novel inhibitor of advanced glycation. Diabetologia, 2002;44:108-114.
50. Kilhovd K, Giardino I, Torjesen PA, Birkeland K I, Berg T J and Thornalley P J. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes, Metabolism, 2007;52:163- 167.
51. Hammes H P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin, J, Bierhaus A, Nawroth P, Hannak D and Neumaier M. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med.2003;9:294-299.
52. Thornalley P J, Jahan I and Nig R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cellsduring hyperglycaemia by thiamine in vitro. J. Biochem. 2001;129:543-549.
53. Babizhayev M, Deyev A. and Yermakova V. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs RD. 2002;3(2):87-103.
54. Price D L, Rhett P M and Thorpe S R.Chelating activity of advanced glycation end-product inhibitors. J Biol Chem, 2001;276(52):48967-48972.
55. Hipkiss A and Brownson C. Carnosine reacts with protein carbonyl groups: another possible role for the anti-aging peptide. Biogerontology. 2001;21:217-22
56. Doggrell S A. Amiodarone – waxed and waned and waxed again. Expert Opin Pharmacother, 2001;2: 1877-1890.
57. Kass M A, Gordon M O and Kymes S M. For the Ocular Hypertension Treatment Study (OHTS) Group. Incorporating the Results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol, 2003;123:1021-1022.
58. Satyavati G V,Gupta A K and Tandon N. Medicinal Plants of India Vol. 2, Indian Council of Medical Research, New Delhi (1987) pp1211-1237.
59. Gupta R K, Kesari A N, Murthy P S, Chandra R, Tandon V and Watal G. Hypoglycemic and anti-diabetic effect of ethanolic extract of leaves of Annona squamosa L. in experimental animals. J. Ethnopharmacol. 2005;99:75–84.
60. Shankar E, Santhosh K T and Paulos C S. Dopaminergic Regulation of Glucose-induced Insulin Secretion through- Dopamine D2 Receptors in the Pancreatic Islets in-Vitro. IUBMB Life. 1980;58(3):157- 163.
61. Sajithlal G B, Chithra P and Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochemical Pharmacology. 1998;56:1607- 1614.
62. Yamaguchi F, Ariga T, Yoshimura Y and Nakazawa H. Anti-oxidative and anti-glycationactivity of garcinol from Garcinia indica fruit rind. J Agri Food Chem. 2000;48:180-185.
63. Kim H Y and Kim K. Protein glycation inhibitory and antioxidative activities of some plant extracts in vitro. J.A.F. Chem. 2003;51:1586-1591.
64. Petkou D, Diamantidis G and Vasilakakis M. Arbutin oxidation by pear (Pyrus communis L. peroxidases. Plant Science. 2002;162:115-119.
65. Arom J. In Vitro Antiglycation Activity of Arbutin. Aresuan University Journal 2005;13(2):35-41
66. Rebecca P, Greenspan, D P, Hartle D K, Swanson R B and James L. Inhibition of Protein Glycation by Extracts of Culinary Herbs and Spices. J. M. F. 2008;11:275-281.
67. Babu P V, Dhandayuthbani, G A, Dowlath R A, Kumar C V, Iqbal M D and Ahamed N. Protective effect of Withania somnifera (Solanaceae) on collagen glycation and crosslinking.: Comparative biochemistry and physiology. Part B. Biochemistry & molecular biology. ISSN 1096-4959, Elsevier, Amsterdam,1994; PAYS-BAS.127-138.
68. Sheikh N, Safari MR, Kashani M, Araghchian M and Zeraat F. Study on the effect of garlic on the in-vitro albumin glycation reaction. Acta Medica Iranica, 2004;42:16-18.
69. Choi S Y, Lee S H, Park K. Kwang B Y and Won L. Glycation inhibitory activity and the identification of an active compound in Plantago asiatica extract. Phytotherapy Research,
2006;22;:323- 329.
70. Jang D S, Kim J M, Lee Y M and Kim J S. Puerariafuran, a New Inhibitor of Advanced Glycation End Products (AGEs) Isolated from the Roots of Pueraria lobata. Chem. Pharm. Bull. 2006;54:1315-1317.
71. Chaiyasut C and Chansakaow S. Inhibitory Effects of Some Thai Plant Extracts on AAPH-induced Protein Oxidation and Protein Glycation. Naresuan Univ. Journal. 2007;15:35- 41.
72. James S A, Auta, R and Goje D. J. In-vitro study on inhibition of glycosylation of methanolic extracts of Hibiscus cannabinus. Science World Journal. 2011;6:7-9.
73. Yadav D P, Chhipa R C and Singh B. Anti-glycation effect of Whitten root (E, nuda) in-vitro condition. IJPSR. 2012; 3(9):3502-3506.
2. Centre for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2011.
3. Horiuchi S. Advanced glycation end products (AGE)- modified proteins and their potential relevance to atherosclerosis. Trend Cardiovasc. Med.1996;6:163-168.
4. Araki N, Ueno N, Chakrabarti B, Morino Y and Horiuchi S. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem.1992;267:10211- 10214.
5. Vorum H, Fisker K, Otagiri M, Pedersen A O and Hansen U. K. Calcium ion binding to clinically relevant chemical modifications of human serum albumin. Clin. Chem.1995;41:1654-1661.
6. Peters T. In All About Albumin: Biochemistry, Genetics, and Medical Applications. Academic Press: San Diego,1996;12; 102-126.
7. Iberg N and Fluckiger R. Nonenzymatic glycosylation of albumin in vivo. J. Biol.Chem.1986;261; 13542-13545.
8. Stewart I. I, Thomson T and Figeys D. 18O labeling: A tool for proteomics. Rapid.J. 2001;34:12-18.
9. Schnolzer M, Jedrzejewski P and Lehmann WD. Proteasecatalyzedincorporation of 18O intopeptide fragments and its application for protein225sequencing by electrospray and matrix-assisted laser desorption/ionization massspectrometry. Electrophoresis. 2005;17:945-953.
10. Wa C, Cerny L and Hage D S. Identification and quantitative studies of protein immobilization sites by stable isotope labeling and mass spectrometry. Anal.Chem.2006;78:7967- 7977.
11. Armbuster D. A Fructosaminase: Structure, analysis and clinical usefulness. Clin. Chem.1987;33:2153-2163.
12. Abordo E A and Thornalley P J. In Pro-inflammatory cytokine synthesis by humanmonocytes induced by proteins minimally-modified by methylglyoxal. TRSC: Cambridge, UK, 1998;12; 357-362.
13. Kouzuma T, Usami T, Yamakoshi M, Takahashi M and Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin. Chim. Acta. 2002;324:61-71.
14. Lapolla A, Fedele D, Seraglia R, Catinella S, Baldo L, Aronica R and Traldi P A. New effective method for the evaluation of glycated intact plasma proteins in diabetic subjects. Diabetologia.1995;38:1076-1081.
15. Mirgorodskaya O A, Kozmin Y P, Titov M I., Korner R, Sonksen C P and Roepstorff P. Quantitation of peptides and proteins by matrix-assisted laser desorption/ionization mass spectrometry using 18O-labeled internal standards. Rapid. Comm. Mass. Spec. 2000;14:1226-1232.226.
16. Takeuchi M, Kikuchi S, Sasaki N, Suzuki T. Iwaki M, Bucahe R and Yamagishi S. Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease. Curr. Alzheimer Res.2004;1:39-46.
17. Basta G, Schmidt A M and Decaterina R. Advanced glyca- tion end products and vascular inflammation: Implications for accelerated atherosclerosis in diabetes. Cardiovascular Research. 2004;63:582-592.
18. Cerami A, Stevens V J and Monnier V M. Role of nonenzymatic glycosylation in the development of the squealed of diabetes mellitus. Metabolism. 1979;28:431-437.
19. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. Journal of Hypertension, 2003;21:3-12
20. Peyroux J and Sternberg M. Advanced glycation endproducts (AGEs):Pharmacological inhibition in diabetes. Pathol Biol. 2006;54:405-419.
21. Schmidt H, Hofmann H and Henary M. No NO from NO synthase. Proc Nat Aad Sci USA. 1996;93:13712-13717
22. Saxena P, Saxena A K and Monnier V M. High galactose levels in vitro and in vivo impair ascorbate regeneration and increase ascorbate-mediated glycation in cultured rat lens. Exper. Eye Res.1996;63:535-545.
23. Kyselova Z, Stefek M and Bauer V. Pharmacological prevention of diabetic cataract. J.Diab.Compli. 2004;18:129-140.
24. Khalifah R G, Baynes J W and Hudson B G. Amadorins: novel post-Amadori inhibitors of advancedglycation reactions. Biochem. Biophys. Res.Commun.1999;257:251-258.
25. Kousar K. Diabetices & metabolisms (2007),32:123-129.
26. Lubeg G, Widness J A, Hayde M, Menzel D and Pollak A. Hydroxyl radical generation in oxygen-treated infants. Pediatrics. 1997;100:700-704.
27. McLean WG. The role of axonal cytoskeleton in diabetic neuropathy. Neurochem Res. 1997;22:951-956.
28. Bonnefont-Rousselot, D. Antioxidant and anti-AGE therapeutics, J Soc Biol. 2001;195(4):391-398.
29. Jin-Bae K, Byeong W, Sungha P, Ki-Chul H, Bong-Soo C, Yangsoo J, Hyun,C La nd Moon-Hyoung L. Alagebrium Chloride, a Novel Advanced Glycation End-Product cross linkage breaker, inhibits neointimal proliferation in a diabetic rat carotid balloon injury model. KCJ. 2010;40:520-526.
30. Nilsso E H. Age-related changes in cobalamin (vitamin B12) handling. Implications for therapy. Drugs Aging. 1999;12(4);277-292.
31. Thornalley P J. Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans. 2003;31:1343-1348.
32. Rahbar S and Figarola J L. Novel inhibitors of advanced glycation end products. Endocrinol. Metab. Agents. 2002;2;:135– 161.
33. Rahbar S, Natarajan R, Yerneni K, Scott S, Gonzales N and Nadler J L. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta. 2000;301(1-2):65-77.
34. Sakai M, Oimomi M and Kasuga M. Experimental studies on the role of fructose in the development of diabetic complications. Kobe J. Med. Sci. 2002;48(5-6):125-136.
35. Rackovsky S and Scheraga H A. The crystal structure of a hydrated gramicidin S–urea complex. Proc. Natl Acad. Sci. USA.1980;77:6965–6967
36. Jyothirmayi G. Effects of Metformin on collagen glycation and diastolic dysfunction. Pharmacol Ther. 1998;3:319-326.
37. Beisswenger J P, Howell S K and Touchette A. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes. 2002;48 (1):198-202.
38. Stitt A, Gardiner T, Alderson N, Canning P, Frizzel N, Duffy N, Boyle C, Januszewski A, Chachich M, Baynes J W and Thorpe S R. The AGE inhibitor pyridoxamine inhibits development of retinopathy inexperimental diabetes. Diabetes. 2002;51:2826-2832.
39. Alderson N L, Chachich M E, Youssef N N, Beattie R J, Nachtigal M, Thorpe R and Baynes J W. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 2003;63:2123-2133.
40. Metz T O, Alderson N L, Chachich M E, Thorpe S R and Baynes J W. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J Biol Chem. 2003;278:42012-42019.
41. Fu M X, Wells K, Blackledge J A, Lyons T J, Thorpe S R and Baynes J W. Glycation, glycoxidation, and cross-linking of collagen by glucose.Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676- 683.
42. Voziyan P A and Hudson B G. “Pyridoxamine as a multifunctionalpharmaceutical: targeting pathogenic glycation and oxidative damage.” Cell Mol Life Sci. 2005;62(15):1671- 81.
43. Baynes J W. The role of AGEs in aging: Causation or correlation. Exp. Gerontol.1991;36:1527-1537.
44. McPherson J D, Shilton B H and Walton D J. Role of fructose in glycation and cross-linking of proteins. Biochemistry. 1998;27(6):.1901-1907.
45. Menzel E J, Reihsner R. Novel inhibitors of advanced glycation end products. Diabetologia. 1991;3412-16.
46. Zhang C, Sun A, et al. “Aspirin for primary prevention of cardiovascular events in patients with diabetes: A metaanalysis. Diabetes Res Clin Pract . 2010;87(2): 211-218.
47. Ahmed N. Advanced glycation endproducts role in pathology of diabetic complications. Diabetes Res. Clin. Pract. 2005;67:3-21.
48. Duraisamy Y, Gaffney J, Slevin M, Smith CA, Williamson K, Ahmed N. Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia,advancedglycation endproducts and glycated basic fibroblast growth factor in cultured bovineaorticendothelial cells: comparison with aminoguanidine. Molecular and Cellular Biochemistry. 2003;246:143– 153.
49. Forbes J M, Soulis T and Thallas V. Renoprotective effects of novel inhibitor of advanced glycation. Diabetologia, 2002;44:108-114.
50. Kilhovd K, Giardino I, Torjesen PA, Birkeland K I, Berg T J and Thornalley P J. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes, Metabolism, 2007;52:163- 167.
51. Hammes H P, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin, J, Bierhaus A, Nawroth P, Hannak D and Neumaier M. (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat. Med.2003;9:294-299.
52. Thornalley P J, Jahan I and Nig R. Suppression of the accumulation of triosephosphates and increased formation of methylglyoxal in human red blood cellsduring hyperglycaemia by thiamine in vitro. J. Biochem. 2001;129:543-549.
53. Babizhayev M, Deyev A. and Yermakova V. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs RD. 2002;3(2):87-103.
54. Price D L, Rhett P M and Thorpe S R.Chelating activity of advanced glycation end-product inhibitors. J Biol Chem, 2001;276(52):48967-48972.
55. Hipkiss A and Brownson C. Carnosine reacts with protein carbonyl groups: another possible role for the anti-aging peptide. Biogerontology. 2001;21:217-22
56. Doggrell S A. Amiodarone – waxed and waned and waxed again. Expert Opin Pharmacother, 2001;2: 1877-1890.
57. Kass M A, Gordon M O and Kymes S M. For the Ocular Hypertension Treatment Study (OHTS) Group. Incorporating the Results of the Ocular Hypertension Treatment Study into clinical practice. Arch Ophthalmol, 2003;123:1021-1022.
58. Satyavati G V,Gupta A K and Tandon N. Medicinal Plants of India Vol. 2, Indian Council of Medical Research, New Delhi (1987) pp1211-1237.
59. Gupta R K, Kesari A N, Murthy P S, Chandra R, Tandon V and Watal G. Hypoglycemic and anti-diabetic effect of ethanolic extract of leaves of Annona squamosa L. in experimental animals. J. Ethnopharmacol. 2005;99:75–84.
60. Shankar E, Santhosh K T and Paulos C S. Dopaminergic Regulation of Glucose-induced Insulin Secretion through- Dopamine D2 Receptors in the Pancreatic Islets in-Vitro. IUBMB Life. 1980;58(3):157- 163.
61. Sajithlal G B, Chithra P and Chandrakasan G. Effect of curcumin on the advanced glycation and cross-linking of collagen in diabetic rats. Biochemical Pharmacology. 1998;56:1607- 1614.
62. Yamaguchi F, Ariga T, Yoshimura Y and Nakazawa H. Anti-oxidative and anti-glycationactivity of garcinol from Garcinia indica fruit rind. J Agri Food Chem. 2000;48:180-185.
63. Kim H Y and Kim K. Protein glycation inhibitory and antioxidative activities of some plant extracts in vitro. J.A.F. Chem. 2003;51:1586-1591.
64. Petkou D, Diamantidis G and Vasilakakis M. Arbutin oxidation by pear (Pyrus communis L. peroxidases. Plant Science. 2002;162:115-119.
65. Arom J. In Vitro Antiglycation Activity of Arbutin. Aresuan University Journal 2005;13(2):35-41
66. Rebecca P, Greenspan, D P, Hartle D K, Swanson R B and James L. Inhibition of Protein Glycation by Extracts of Culinary Herbs and Spices. J. M. F. 2008;11:275-281.
67. Babu P V, Dhandayuthbani, G A, Dowlath R A, Kumar C V, Iqbal M D and Ahamed N. Protective effect of Withania somnifera (Solanaceae) on collagen glycation and crosslinking.: Comparative biochemistry and physiology. Part B. Biochemistry & molecular biology. ISSN 1096-4959, Elsevier, Amsterdam,1994; PAYS-BAS.127-138.
68. Sheikh N, Safari MR, Kashani M, Araghchian M and Zeraat F. Study on the effect of garlic on the in-vitro albumin glycation reaction. Acta Medica Iranica, 2004;42:16-18.
69. Choi S Y, Lee S H, Park K. Kwang B Y and Won L. Glycation inhibitory activity and the identification of an active compound in Plantago asiatica extract. Phytotherapy Research,
2006;22;:323- 329.
70. Jang D S, Kim J M, Lee Y M and Kim J S. Puerariafuran, a New Inhibitor of Advanced Glycation End Products (AGEs) Isolated from the Roots of Pueraria lobata. Chem. Pharm. Bull. 2006;54:1315-1317.
71. Chaiyasut C and Chansakaow S. Inhibitory Effects of Some Thai Plant Extracts on AAPH-induced Protein Oxidation and Protein Glycation. Naresuan Univ. Journal. 2007;15:35- 41.
72. James S A, Auta, R and Goje D. J. In-vitro study on inhibition of glycosylation of methanolic extracts of Hibiscus cannabinus. Science World Journal. 2011;6:7-9.
73. Yadav D P, Chhipa R C and Singh B. Anti-glycation effect of Whitten root (E, nuda) in-vitro condition. IJPSR. 2012; 3(9):3502-3506.
Published
2019-09-06
How to Cite
Nadeem Mohammad Khan, Gothalwal R. (2019). Contemplate Synthetic and Herbal origin provisions for non-enzymatic Glycation (NEGs) inhibition. The Indian Practitioner, 67(10), 622-629. Retrieved from https://articles.theindianpractitioner.com/index.php/tip/article/view/738
Section
Review article
